BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 30100079)

  • 1. Clinical Potential of Estrogen and Progesterone Receptor Imaging.
    Linden HM; Peterson LM; Fowler AM
    PET Clin; 2018 Jul; 13(3):415-422. PubMed ID: 30100079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
    Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.
    Kurland BF; Wiggins JR; Coche A; Fontan C; Bouvet Y; Webner P; Divgi C; Linden HM
    Oncologist; 2020 Oct; 25(10):835-844. PubMed ID: 32374053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer.
    Fowler AM; Chan SR; Sharp TL; Fettig NM; Zhou D; Dence CS; Carlson KE; Jeyakumar M; Katzenellenbogen JA; Schreiber RD; Welch MJ
    J Nucl Med; 2012 Jul; 53(7):1119-26. PubMed ID: 22669982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[
    Katzenellenbogen JA
    Nucl Med Biol; 2021 Jan; 92():24-37. PubMed ID: 32229068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients.
    Koleva-Kolarova RG; Greuter MJ; van Kruchten M; Vermeulen KM; Feenstra T; Buskens E; Glaudemans AW; de Vries EF; de Vries EG; Hospers GA; de Bock GH
    Br J Cancer; 2015 May; 112(10):1617-25. PubMed ID: 25880006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal noninvasive imaging of progesterone receptor as a predictive biomarker of tumor responsiveness to estrogen deprivation therapy.
    Chan SR; Fowler AM; Allen JA; Zhou D; Dence CS; Sharp TL; Fettig NM; Dehdashti F; Katzenellenbogen JA
    Clin Cancer Res; 2015 Mar; 21(5):1063-70. PubMed ID: 25520392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating
    Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM
    J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16α-[
    Mankoff D; Balogová S; Dunnwald L; Dehdashti F; DeVries E; Evangelista L; Van Kruchten M; Vaz SC; Fowler A; Linden H; Ulaner GA
    J Nucl Med; 2024 Feb; 65(2):221-223. PubMed ID: 38071554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.
    Gemignani ML; Patil S; Seshan VE; Sampson M; Humm JL; Lewis JS; Brogi E; Larson SM; Morrow M; Pandit-Taskar N
    J Nucl Med; 2013 Oct; 54(10):1697-702. PubMed ID: 23970364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular imaging using PET for breast cancer.
    Kurihara H; Shimizu C; Miyakita Y; Yoshida M; Hamada A; Kanayama Y; Yonemori K; Hashimoto J; Tani H; Kodaira M; Yunokawa M; Yamamoto H; Watanabe Y; Fujiwara Y; Tamura K
    Breast Cancer; 2016 Jan; 23(1):24-32. PubMed ID: 25917108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma.
    van Kruchten M; Glaudemans AW; de Vries EF; Beets-Tan RG; Schröder CP; Dierckx RA; de Vries EG; Hospers GA
    J Nucl Med; 2012 Feb; 53(2):182-90. PubMed ID: 22241912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Imaging Assessment of Hormonally Sensitive Breast Cancer: An Appraisal of 2-[18F]-Fluoro-2-Deoxy-Glucose and Newer Non-2-[18F]-Fluoro-2-Deoxy-Glucose PET Tracers.
    Yadav D; Kumar R; Phulia A; Basu S; Alavi A
    PET Clin; 2022 Jul; 17(3):399-413. PubMed ID: 35717099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using
    Jager A; de Vries EGE; der Houven van Oordt CWM; Neven P; Venema CM; Glaudemans AWJM; Wang Y; Bagley RG; Conlan MG; Aftimos P
    Breast Cancer Res; 2020 Sep; 22(1):97. PubMed ID: 32912274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
    Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
    Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [18F]-fluoroestradiol quantitative PET imaging to differentiate ER+ and ERα-knockdown breast tumors in mice.
    Paquette M; Ouellet R; Archambault M; Croteau É; Lecomte R; Bénard F
    Nucl Med Biol; 2012 Jan; 39(1):57-64. PubMed ID: 22079037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT.
    van Kruchten M; de Vries EF; Arts HJ; Jager NM; Bongaerts AH; Glaudemans AW; Hollema H; de Vries EG; Hospers GA; Reyners AK
    J Nucl Med; 2015 Jan; 56(1):50-5. PubMed ID: 25476534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of progesterone receptors in breast carcinoma by PET with 21-18F-fluoro-16α,17α-[(R)-(1'-α-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione.
    Dehdashti F; Laforest R; Gao F; Aft RL; Dence CS; Zhou D; Shoghi KI; Siegel BA; Katzenellenbogen JA; Welch MJ
    J Nucl Med; 2012 Mar; 53(3):363-70. PubMed ID: 22331216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations and Technical Aspects of 16α-[18F]Fluoro-17β-Estradiol PET to Image the Estrogen Receptor In Vivo: The Groningen Experience.
    Venema CM; Apollonio G; Hospers GA; Schröder CP; Dierckx RA; de Vries EF; Glaudemans AW
    Clin Nucl Med; 2016 Nov; 41(11):844-851. PubMed ID: 27607175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer
    Paquette M; Lavallée É; Phoenix S; Ouellet R; Senta H; van Lier JE; Guérin B; Lecomte R; Turcotte ÉE
    J Nucl Med; 2018 Feb; 59(2):197-203. PubMed ID: 28798032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.